Rapport Therapeutics (RAPP) Projected to Post Earnings on Thursday

Rapport Therapeutics (NASDAQ:RAPP) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Rapport Therapeutics to post earnings of ($1.20) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Rapport Therapeutics (NASDAQ:RAPP) last issued its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, analysts expect Rapport Therapeutics to post ($4.08) EPS for the current fiscal year and ($5.05) EPS for the next fiscal year.

Rapport Therapeutics Trading Up 0.3%

Shares of Rapport Therapeutics stock opened at $25.13 on Tuesday. Rapport Therapeutics has a twelve month low of $22.06 and a twelve month high of $52.93. The stock has a market capitalization of $1.21 billion, a P/E ratio of -8.27 and a beta of 1.22. The business’s fifty day moving average price is $36.24 and its 200 day moving average price is $35.56.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. William Blair initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating for the company. Wall Street Zen lowered Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Wells Fargo & Company reduced their price objective on Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 21st. HC Wainwright reiterated a “buy” rating and set a $66.00 target price on shares of Rapport Therapeutics in a report on Tuesday, October 20th. Finally, BTIG Research increased their target price on shares of Rapport Therapeutics from $75.00 to $89.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Rapport Therapeutics presently has an average rating of “Buy” and a consensus target price of $68.36.

Insider Buying and Selling at Rapport Therapeutics

In related news, Director Steven M. Paul purchased 35,714 shares of the stock in a transaction that occurred on Thursday, October 22nd. The stock was purchased at an average cost of $27.28 per share, for a total transaction of $974,277.92. Following the acquisition, the director owned 77,380 shares in the company, valued at approximately $2,110,926.40. This trade represents a 85.71% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Cheryl Gault sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $33.19, for a total value of $331,900.00. Following the completion of the transaction, the chief operating officer directly owned 139,914 shares in the company, valued at $4,643,745.66. This trade represents a 6.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have acquired 1,031,174 shares of company stock worth $22,023,898 and have sold 97,976 shares worth $4,391,729. Insiders own 12.48% of the company’s stock.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.